CA3141571A1 - 1h-imidazo[4,5-b]pyridin-2(3h)-one compounds and derivatives for inhibition of janus kinase 1 - Google Patents

1h-imidazo[4,5-b]pyridin-2(3h)-one compounds and derivatives for inhibition of janus kinase 1 Download PDF

Info

Publication number
CA3141571A1
CA3141571A1 CA3141571A CA3141571A CA3141571A1 CA 3141571 A1 CA3141571 A1 CA 3141571A1 CA 3141571 A CA3141571 A CA 3141571A CA 3141571 A CA3141571 A CA 3141571A CA 3141571 A1 CA3141571 A1 CA 3141571A1
Authority
CA
Canada
Prior art keywords
pyridin
imidazo
pyrazol
trifluoro
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3141571A
Other languages
English (en)
French (fr)
Inventor
Santosh Kumar Rai
Mahadev BANDGAR
Sazid ALI
Himanshu RAI
Amol Pandurang Gunjal
Rakesh Iswar PATIL
Srinivasa Reddy Bapuram
Anil Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mankind Pharma Ltd
Original Assignee
Mankind Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mankind Pharma Ltd filed Critical Mankind Pharma Ltd
Publication of CA3141571A1 publication Critical patent/CA3141571A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3141571A 2019-05-28 2020-05-26 1h-imidazo[4,5-b]pyridin-2(3h)-one compounds and derivatives for inhibition of janus kinase 1 Pending CA3141571A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201911021098 2019-05-28
IN201911021098 2019-05-28
PCT/IN2020/050471 WO2020240586A1 (en) 2019-05-28 2020-05-26 Novel compounds for inhibition of janus kinase 1

Publications (1)

Publication Number Publication Date
CA3141571A1 true CA3141571A1 (en) 2020-12-03

Family

ID=73553608

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3141571A Pending CA3141571A1 (en) 2019-05-28 2020-05-26 1h-imidazo[4,5-b]pyridin-2(3h)-one compounds and derivatives for inhibition of janus kinase 1

Country Status (11)

Country Link
US (1) US12516056B2 (https=)
EP (1) EP3976612A4 (https=)
JP (1) JP7592029B2 (https=)
CN (1) CN114174294B (https=)
AU (1) AU2020284742B2 (https=)
BR (1) BR112021023635A2 (https=)
CA (1) CA3141571A1 (https=)
MX (1) MX2021014361A (https=)
TW (1) TWI839524B (https=)
WO (1) WO2020240586A1 (https=)
ZA (1) ZA202109183B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023526521A (ja) * 2020-05-21 2023-06-21 ステムシナジー セラピューティクス， インク． Ｎｏｔｃｈ阻害剤及びそれらの使用
WO2022166796A1 (zh) * 2021-02-05 2022-08-11 上海齐鲁制药研究中心有限公司 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途
PE20250019A1 (es) * 2021-05-06 2025-01-07 Exscientia Ai Ltd MODULADORES DE PKC-theta
WO2022234298A1 (en) * 2021-05-06 2022-11-10 Exscientia Ai Limited Pkc-theta modulators
EP4452944A1 (en) * 2021-12-22 2024-10-30 Icagen, LLC Cyclopropyl compounds
CN117050074B (zh) * 2022-05-05 2025-08-12 中国药科大学 一类吡啶联咪唑并吡啶化合物及其制备方法与用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5002851B2 (ja) * 2005-01-20 2012-08-15 独立行政法人理化学研究所 イミダゾピリジン誘導体
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
UY29825A1 (es) 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
SG10202003901UA (en) * 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
EP2244711A4 (en) * 2008-02-04 2011-08-24 Cytokinetics Inc CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
US20110201599A1 (en) * 2008-07-03 2011-08-18 Exelixis, Inc. CDK Modulators
WO2010036316A1 (en) 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
FI124118B (fi) * 2011-06-13 2014-03-31 Reijo Uolevi Hautalahti Aurinkoenergian avulla sähköä ja lämpöä tuottava voimala
KR20130076046A (ko) * 2011-12-28 2013-07-08 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체
ES2567552T3 (es) * 2012-01-30 2016-04-25 Cephalon, Inc. Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos
CN104140426B (zh) * 2013-05-07 2017-02-01 上海汇伦生命科技有限公司 嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途
US10253023B2 (en) 2014-10-06 2019-04-09 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
CN105837572B (zh) 2015-02-02 2019-04-19 四川大学 N-取代苯基酰胺衍生物及其制备方法和用途
CN106146504B (zh) * 2015-04-17 2018-09-07 上海汇伦生命科技有限公司 一种杂环并咪唑类化合物、其药物组合物及其制备方法和用途
ES2830446T3 (es) 2015-12-11 2021-06-03 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Derivado de azetidina, método de preparación del mismo y uso del mismo
CN109641892B (zh) * 2016-08-16 2021-07-02 默克专利有限公司 用作可逆btk抑制剂的2-氧代-咪唑并吡啶及其用途
GB201717260D0 (en) 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
CN113508114B (zh) * 2019-02-27 2024-03-26 四川科伦博泰生物医药股份有限公司 以氮杂环丁烷衍生物为活性成分的口服药物组合物、其制备方法及用途

Also Published As

Publication number Publication date
TW202110838A (zh) 2021-03-16
JP7592029B2 (ja) 2024-11-29
ZA202109183B (en) 2022-08-31
EP3976612A4 (en) 2023-04-26
US20220235046A1 (en) 2022-07-28
CN114174294A (zh) 2022-03-11
EP3976612A1 (en) 2022-04-06
CN114174294B (zh) 2024-10-25
MX2021014361A (es) 2022-04-06
AU2020284742B2 (en) 2026-03-05
US12516056B2 (en) 2026-01-06
BR112021023635A2 (pt) 2022-02-01
JP2022534510A (ja) 2022-08-01
AU2020284742A1 (en) 2022-02-03
WO2020240586A1 (en) 2020-12-03
TWI839524B (zh) 2024-04-21

Similar Documents

Publication Publication Date Title
AU2022263410B2 (en) Carboxy-benzimidazole glp-1r modulating compounds
CA3141571A1 (en) 1h-imidazo[4,5-b]pyridin-2(3h)-one compounds and derivatives for inhibition of janus kinase 1
JP7001682B2 (ja) 置換１Ｈ－イミダゾ［４，５－ｂ］ピリジン－２（３Ｈ）－オン及びＧＬＵＮ２Ｂ受容体調節因子としてのそれらの使用
AU2016231289B2 (en) Benzazepine dicarboxamide compounds
US8338610B2 (en) Pyridinyl compounds useful as intermediates
EP3414234B1 (en) Bruton's tyrosine kinase inhibitors
RU2686117C1 (ru) Конденсированные производные имидазола и пиразола в качестве модуляторов активности tnf
JP6182549B2 (ja) 選択的サイクリン依存性キナーゼ阻害剤としてのピラゾロ−トリアジン誘導体
AU2018353759B2 (en) Heterocyclic compound as a protein kinase inhibitor
AU2005332339B2 (en) Furanopyridine derivatives as ACK1 and Lck modulators
MXPA06015192A (es) Inhibidores de pirrolotriazina cinasa.
AU2010339533A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
SK11322003A3 (en) 6-Substituted pyrido-pyrimidines
TW202210466A (zh) 治療性化合物
AU2019353144B2 (en) Compounds and compositions for treating conditions associated with APJ receptor activity
TW202122382A (zh) 乙內醯脲衍生物
EP3159341A1 (en) Pyridino[1,2-a]pyrimidone analogue used as pi3k inhibitor
TW202444350A (zh) 作為ｇｌｐ—１ｒ激動劑之化合物
CN102656172B (zh) 8-氧代二氢嘌呤衍生物
RU2833828C2 (ru) Новые соединения для ингибирования янус-киназы 1
KR20190064555A (ko) 단백질 키나제 억제제로서의 헤테로고리 화합물
CA3008653C (en) Bruton's tyrosine kinase inhibitors
KR20250029065A (ko) TRPM3-매개 장애를 치료하기 위한 피라졸로[1,5-a]피리딘 유도체
TW202602878A (zh) Ａｋｔ１調節劑
EA051879B1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220518

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240926

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241007

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250411

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250411

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250424

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250424

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251223

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260305

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260305